Clear Harbor Asset Management’s Novavax NVAX Stock Holding History

Clear Harbor Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-975	Closed	-$36K	–	260
2018 Q4	$36K	Hold	975	–	–	0.01%	234
2018 Q3	$36K	Hold	975	–	–	0.01%	251
2018 Q2	$26K	Hold	975	–	–	﹤0.01%	252
2018 Q1	$41K	Buy	+975	New	+$39.2K	0.01%	228

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Clear Harbor Asset Management's NVAX Position: Q1 2019 in Review

Clear Harbor Asset Management sold out of Novavax (NVAX) in Q1 2019, closing a stake of 975 shares — an estimated $36K sold.

Clear Harbor Asset Management first reported a position in NVAX in Q1 2018 and held it in 4 quarters. The position peaked at $41K in Q1 2018. 140 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

Clear Harbor Asset Management reported no remaining Novavax position as of Q1 2019 after selling out during the quarter.
Clear Harbor Asset Management sold 975 Novavax shares in Q1 2019, an estimated $36K.
Clear Harbor Asset Management first reported a position in Novavax in Q1 2018 and held it in 4 quarters.
Clear Harbor Asset Management's Novavax position peaked at $41K in Q1 2018.
140 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on Clear Harbor Asset Management's 13F filing for Q1 2019, filed 19 Apr 2019.